In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $26. The company’s shares closed yesterday at $6.43.
“We are reiterating the Overweight rating and $26 PT for TXMD stock. FDA approval of TX-004, now known as Imvexxy, for treating vulvar vaginal atrophy (VVA) sets the company on a course to bring two important therapies to the market for treating symptoms associated with menopause, in our opinion. With the approval, TXMD can access $75 million from the recently-struck loan agreement. The PDUFA date for TX-001, an investigational drug for treating vasomotor symptoms (VMS, aka, hot flushes) of menopause is October 28. If approved, 2018 should be regarded as the most important year in the company’s history, in our view.”
According to TipRanks.com, Tanner is a 4-star analyst with an average return of 7.6% and a 53.7% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $15.
The company has a one-year high of $7.01 and a one-year low of $3.83. Currently, TherapeuticsMD has an average volume of 2.38M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.